Rasha Abdelhady, Osama A Mohammed, Ahmed S Doghish, Rabab S Hamad, Mustafa Ahmed Abdel-Reheim, Mohannad Mohammad S Alamri, Muffarah Hamid Alharthi, Jaber Alfaifi, Masoud I E Adam, Abdullah Hassan Alhalafi, Nahid A Mohammed, Adamu Imam Isa, Sameh Abdel-Ghany, Mohammed A Attia, Elsayed A Elmorsy, Tohada M Al-Noshokaty, Yousra Nomier, Walaa A El-Dakroury, Sameh Saber
Accumulating evidence suggests that dysregulation of FOXO3a plays a significant role in the progression of various malignancies, including hepatocellular carcinoma (HCC). FOXO3a inactivation, driven by oncogenic stimuli, can lead to abnormal cell growth, suppression of apoptosis, and resistance to anticancer drugs. Therefore, FOXO3a emerges as a potential molecular target for the development of innovative treatments in the era of oncology. Linagliptin (LNGTN), a DPP-4 inhibitor known for its safe profile, has exhibited noteworthy anti-inflammatory and anti-oxidative properties in previous in vivo studies...
February 29, 2024: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology